Generic Optiray 300 Availability

See also: Generic Optiray 240, Generic Optiray 320, Generic Optiray 350

Optiray 300 is a brand name of ioversol, approved by the FDA in the following formulation(s):

OPTIRAY 300 (ioversol - injectable;injection)

  • Manufacturer: MALLINCKRODT
    Approval date: January 22, 1992
    Strength(s): 64% [RLD]
  • Manufacturer: MALLINCKRODT
    Approval date: May 13, 1999
    Strength(s): 64% [RLD]

Has a generic version of Optiray 300 been approved?

No. There is currently no therapeutically equivalent version of Optiray 300 available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Optiray 300. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Optiray 300.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web5)